Amgen
New breakthrough for CGRP migraine treatments
February 6, 2018Research and Development Allergan, Amgen, CGRP, Novartis, biotech, drugs, pharma, pharmaceutical
Allergan had a rough year in 2017, dropping by close to $80 a share from February 2017 to this month. …
FDA clears Amgen’s bone drug for multiple myeloma
January 8, 2018Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma
Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
Kirin Holdings to withdraw from 30 year venture with Amgen, sell shares for $780m
October 31, 2017Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Kirin, joint venture, pharma
Japanese firm Kirin Holdings has announced its intention to withdraw from a joint research collaboration with Amgen, saying it would …
Mylan and Biocon Neulasta biosimilar knocked back by FDA
October 11, 2017Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical
Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …
CytomX scores deal with Amgen worth potential $1.5bn
October 4, 2017Research and Development, Sales and Marketing Amgen, biotech, cytomx, drugs, pharma, pharmaceutical
CytomX Therapeutics and Amgen have signed a deal that could be worth a potential $1.5 billion. The agreement will see …
Five more biosimilar-free years for AbbVie’s megablockbuster
September 28, 2017Medical Communications, Sales and Marketing AbbVie, Amgen, Amjevita, Humira, biotech, drugs, pharma, pharmaceutical
Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the …
FDA approves first-ever biosimilar for cancer treatment
September 15, 2017Medical Communications, Sales and Marketing Amgen, Cancer, FDA, Mvasi, avastin, biosimilar
The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer …
Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
September 7, 2017Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
FDA refuses approval of Amgen osteoporosis drug
July 17, 2017Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical
Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …
Pfizer’s biosimilar gets a second knock-back from FDA
June 23, 2017Medical Communications, Sales and Marketing Amgen, Epogen, FDA, Pfizer
Pfizer has been dealt a stinging blow by the FDA, after it received a second complete response letter from the …
Breakthrough treatment for ovarian cancer displays promising results
June 5, 2017Research and Development, Sales and Marketing Amgen, Cancer, ICR, ovarian cancer
A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking …
Amgen hit by major safety blow on osteoporosis drug
May 22, 2017Research and Development, Sales and Marketing Amgen, Romosozumab, UCB SA
Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved …
Amgen accuses biosimilar producer of ‘massive conspiracy’
March 9, 2017Medical Communications Amgen, Coherus, Neulasta, biosimilars
Amgen has filed a lawsuit in a Californian state court against Coherus Biosciences, suggesting that Coherus had stolen trade secrets. …
Sanofi & Regeneron deflect Amgen’s legal marketing block on Praluent
February 9, 2017Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, praluent
Sanofi and Regeneron have successfully won in a US Court ruling calling for the suspension of the permanent injunction of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
